We intend to maximize the value of the promising drug candidates that result from our novel drug discovery research. To that end, we carefully evaluate business development opportunities, seeking collaborations that have significant potential to build value and create returns for our investors. Our current collaborations are outlined below. We continue to explore potential collaborations for our drug candidates.

Everest Medicines Limited – Ralinepag and Etrasimod in Greater China and Select Asian Countries  (entering Ph 3)

We and Everest Medicines have a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the “Territories”). The goal is to leverage Everest capabilities in the evolving regulatory landscape in China to enhance the drug approval process related to transformative foreign drugs. Under the terms of the agreement, Arena has granted Everest exclusive rights to develop and commercialize ralinepag and etrasimod in the Territories. In return, Arena received an upfront payment and is eligible to receive development and commercial milestone payments as well as royalties on net annual sales of both ralinepag and etrasimod. The parties plan to collaborate on development on both products; however, Everest is generally responsible for funding development and commercialization in the Territories.

Axovant – Nelotanserin Development (Ph 2)

We and Axovant Sciences Ltd. have a Development, Marketing and Supply Agreement for nelotanserin, Arena’s internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Axovant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials. Axovant has an ongoing Phase 2 clinical trial with nelotanserin, in patients with dementia with Lewy bodies (DLB) or Parkinson’s disease dementia (PDD) who are experiencing REM sleep behavior disorder (RBD). Axovant is responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Axovant.

Nelotanserin has not been approved by the US Food and Drug Administration or any other regulatory agency.

Boehringer Ingelheim International GmbH – Undisclosed Target (Preclinical)

We and Boehringer Ingelheim have a Research and Licensing Agreement to conduct joint research to identify drug candidates targeting a GPCR that belongs to the group of orphan CNS receptors. The goal is to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications, with the initial focus expected to be psychiatric diseases such as schizophrenia. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

Outpost Medicine, LLC – Undisclosed Target (Preclinical)

We and Outpost Medicine have a Licensing Agreement to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders. Under the terms of the agreement, Arena has granted Outpost exclusive, worldwide rights to develop and commercialize the compound. In return, Arena received an upfront fee comprised of cash and equity and is eligible to receive development and commercial milestone payments and tiered royalties on annual net sales of the compound.

Eisai – BELVIQ (lorcaserin HCI) (Commercial)

We discovered and developed lorcaserin (BELVIQ and BELVIQ XR), which is currently marketed by Eisai or its distributors in the United States, or US, and certain other countries for weight loss. We have granted an exclusive, royalty-bearing license, or transferred intellectual property or other rights, to develop, manufacture and commercialize BELVIQ® (lorcaserin) in all countries and territories of the world. Eisai assumed Arena’s exclusive manufacturing and supply agreements with third-parties to develop and market lorcaserin in South Korea, Taiwan and Israel. Eisai has agreed to make tiered royalty payments to us on the net sales of lorcaserin.

For Belviq®-related inquires please contact Eisai.